

@Laim_Ziz 🎇 linkedin.com/in/Laimdota/ in

Department of Preclinical Imaging and Radiopharmacy Core Facility Metabolomics, Faculty of Medicine, University of Tübingen



Laimdota Zizmare^{1,2,3,4}, Francisco J. Reche-Pérez^{3,4}, Jonathan Cotton^{3,4}, Corinna Henkel⁵, Bernd J. Pichler^{3,4,6,*}, Christoph Trautwein^{1,2,3,4,*}

¹ Core Facility Metabolomics, Faculty of Medicine, University of Tübingen, 72076, Germany. ² The M3 Research Center for Malignome, Metabolome and Microbiome, University of Tübingen, 72076, Germany. ³ Cluster of Excellence iFIT "Image Guided and Functionally Instructed Tumor Therapies "(EXC 2180), University of Tübingen, 72076, Germany. ⁴ Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, 72076, Germany. ⁵ Bruker Daltonics GmbH & Co.KG, 28359 Bremen, Germany. ⁶ German Cancer Research Center, German Cancer Consortium DKTK, Partner Site Tübingen, Germany. * equal contribution

INTRODUCTION

- Cellular senescence, a double-edged sword, initially causes the inhibitory cell-cycle arrest, yet further also initiates the cellular adaptation of the senescence-associated secretory phenotype (SASP), transforming fibroblasts into tumor progressionfavorable pro-inflammatory cells, and ultimately aiding the therapy resistance.
- Aim: unravel the metabolic role of senescence in tumor microenvironment heterogeneity by spatial metabolomic characterization of senescent tumors.

SUMMARY

- The tumor microenvironment is highly heterogenous and therefore needs to be studied spatially.
- > We demonstrate how spatial metabolomics aid the elucidation of the metabolomic and lipid alterations in response to senescence induction and in the areas of senescence tracer localization.
- Subcutaneous liver carcinoma cell senescent and control tumor metabolomics was analyzed by ion mobility time-of-flight spectrometry (timsTOF fleX MALDI-2 imaging) data was acquired at 10 μ m pixel resolution,100 – 1000 m/z.
- Bioactive lipids, including sphingolipids, oxidized phospholipids, arachidonic acid, lipid droplets, and free fatty acids contribute to chronic **inflammatory** state, regulation and amplification of SASP, and cellular membrane remodeling. Hence these are important study targets for potential therapeutic interventions and progression monitoring.





Fructose 1,6-bisph 338.9886 m/z ± 10 ppm 1/K0 0.765 ± 0.02	> 714%
Taurine - 124.0074 m/z ± 10 ppm 1/K0 1.109 ± 0.02	775%
Fructose - 179.0562 m/z \pm 10 ppm 1/K0 0.912 \pm 0.02	670%
Glutathione - 306.0771 m/z ± 10 ppm 1/K0 1.083 ± 0.02	624%
$\cap 0/$	100%

Fig 3. MALDI-2 imaging of negatively ionized metabolites. Example overlapping metabolite spatial distribution illustrates the spatial variability of metabolite distribution and intensity, signifying control tumor core. Senescent tumors visually present increased reactive metabolites. Annotations confirmed with accurate mass, ion mobility and cross collision section (ccs) value match. *Fructose 1,6-bisph. = D-fructose 1,6-bisphosphate*

Fructose 1,6-bisph. **Coriolic Acid** Taurine Uric Acid 50000 30000 20000 0000 Senesc. Senesc. Control Senesc. Control Control Control Senesc.

Fig 4. Example ion intensity box plots and scatter plots showing the increased intensity of D-fructose 1,6-bisphosphate and coriolic acid (13-HODE), and reduced uric acid. Taurine stresses the importance of spatial visualization alongside overall intensity estimation.

> Fig 5. (left) Volcano plot of one negatively ionized MALDI-2 imaging slide run of metabolites and lipids highlights altered omega 3 and 6 fatty acid metabolic pathways in senescent tumors. Phospholipid remodeling was observed in line with the previous quantitative metabolomics findings on cellular composition modifications upon senescence induction ⁽⁴⁾.

ACKNOWLEDGEMENT

The authors thank Johannes Kinzler, Miriam Owczorz, Ramona Stremme, Dennis Haupt, Maren Harant, and the Prof. Lars Zender group for the access to research materials and knowledge. We thank Dr. Andras Kiss for extended support on methodology and training. The research received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Germany's Excellence Strategy-EXC2180-390900677 the Cluster of Excellence iFIT), Bruker Daltonics GmbH, and the Werner Siemens Foundation. Parts of the figures created with Biorender.com, MetaboScape[®], and SCiLS[™] lab.

References: 1. Innes J.K. et al., 2018. https://doi.org/10.1016/j.plefa.2018.03.004. 2. Hong S. et al., 2013. https://doi.org/10.3389/fimmu.2013.00013. 3. Masner M. et al., 2021. https://doi.org/10.1038/s41598-021-94399-8. 4. Knopf P. & Pacheco-Torres J. et al., 2024. https://doi.org/10.1002/nbm.5157.



Contact: **Dr. Laimdota Zizmare Core Facility Metabolomics** Otfried-Müller-Straße 37, 72076 Tübingen, Germany E-mail: Laimdota.Zizmare@med.uni-tuebingen.de

